Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Plus components not separately reported this period.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
FAQ
- What is BridgeBio Pharma's EBIT?
- BridgeBio Pharma (BBIO) reported EBIT of -$105.96M in Q1 2026.
- How has BridgeBio Pharma's EBIT changed year-over-year?
- BridgeBio Pharma's EBIT decreased by 1.5% year-over-year, from -$104.37M to -$105.96M.
- What is the long-term trend for BridgeBio Pharma's EBIT?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EBIT has grown at a -2.4% compound annual growth rate (CAGR), from -$576.63M to -$523.41M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about BridgeBio Pharma's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude